Nemaura Medical rises on completing initial shipment of glucose monitor

Nemaura Medical

07/12/2021 15:05

** Shares of the medical device maker  NMRD.O  rise 4.3% to
$4.30
    ** Co completes initial shipment of sugarBEAT continuous
glucose monitor (CGM) devices to its UK licensee, MySugarWatch
Ltd  urn:newsml:reuters.com:*:nGNXbwV5Df
    ** NMRD's sugarBEAT is a non-invasive and flexible CGM
    ** In May, MySugarWatch placed an initial order for 5,000
CGM devices and 200,000 sensors 
    ** Agreement includes rolling monthly purchase order for up
to an additional 15,000 transmitters and 2.1 million sensors
over the next 24 months 
    ** Stock up ~14% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))